For research use only. Not for therapeutic Use.
Enbezotinib (enantiomer) (Compound 44) is the enantiomer form of Enbezotinib (HY-145565). Enbezotinib is an inhibitor of RET[1].
Catalog Number | I040798 |
CAS Number | 2359650-19-2 |
Synonyms | (3R,7S,17R)-12-fluoro-17-methyl-2,16-dioxa-8,14,19,23,24,26-hexazahexacyclo[22.3.1.03,7.08,27.010,15.021,25]octacosa-1(28),10(15),11,13,21(25),22,26-heptaen-20-one |
Molecular Formula | C21H21FN6O3 |
Purity | ≥95% |
InChI | InChI=1S/C21H21FN6O3/c1-11-6-23-20(29)14-8-25-28-10-17-19(26-18(14)28)27(15-3-2-4-16(15)31-17)9-12-5-13(22)7-24-21(12)30-11/h5,7-8,10-11,15-16H,2-4,6,9H2,1H3,(H,23,29)/t11-,15+,16-/m1/s1 |
InChIKey | BYYQDEOVMILBQT-XFBWCDHKSA-N |
SMILES | CC1CNC(=O)C2=C3N=C4C(=CN3N=C2)OC5CCCC5N4CC6=C(O1)N=CC(=C6)F |
Reference | [1]. Evan W. ROGERS, et, al. Macrocyclic compounds for treating disease. Patent. WO2019126121 A1. |